Neurorehabilitation News

For individuals with ALS, a daily dosing regimen of oral edaravone was nonsuperior to an FDA-approved staggered regimen of the drug plus placebo, according to a poster presented at AANEM.

The FDA has approved an adeno-associated virus vector-based gene therapy to treat both adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency.

Treatment with IV nipocalimab was safe and led to significant reductions in disease expression at 24 weeks in adolescents with generalized myasthenia gravis, according to data presented at AANEM.

An oral therapeutic significantly reduced the number of tumors in adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas, according to topline results from a phase 3 study.

Individuals with a predelivery history of concussion appeared to be at increased risk for severe maternal mental illness, highlighting the importance of screening and supportive care for this high-risk group, according to researchers.

Features of memory retention in cells may result from embedded signaling dynamics in the body, with information stored best in spaced bursts rather than in a single, massed event, according to research from Nature Communications.

IV administration of Uplizna was safe and shown to be more efficacious for those with generalized myasthenia gravis compared with placebo at week 26, according to a presentation from AANEM.

Alterations in white matter integrity were linked to cognitive impairment, and associations were strongest in those with major depressive disorder compared with healthy controls, according to new research.

IV administration of fasudil at two separate doses was safe and well tolerated in a small cohort of individuals with suspected or confirmed ALS, according to new research published in The Lancet.